136 related articles for article (PubMed ID: 3776530)
1. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.
Osamura RY; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530
[TBL] [Abstract][Full Text] [Related]
2. Ultrastructural localization of prolactin in the human pituitary prolactinomas and its changes by bromocriptine treatment.
Osamura RY; Teramoto A; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1123-30. PubMed ID: 3776529
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.
Niwa J; Minase T; Hashi K; Mori M
Virchows Arch B Cell Pathol Incl Mol Pathol; 1987; 53(2):89-96. PubMed ID: 2887062
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: ultrastructural alterations of secretory granules.
Saitoh Y; Koizumi K; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H
Anticancer Res; 1986; 6(5):1149-55. PubMed ID: 3800323
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: special reference to changes in secretory granules by stereological analysis].
Saitoh Y; Koizumi K; Arita N; Hayakawa T; Aono T; Matsumoto K; Mogami H; Mori H
No To Shinkei; 1987 Apr; 39(4):347-54. PubMed ID: 3593602
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical, electron microscopic, and morphometric studies of human prolactinomas after short-term bromocriptine treatment.
Niwa J; Minase T; Mori M; Hashi K
Surg Neurol; 1987 Nov; 28(5):339-44. PubMed ID: 3660204
[TBL] [Abstract][Full Text] [Related]
7. Decreased prolactin level in secretory granules and their increased exocytosis in estrogen-induced pituitary hyperplasia in rats treated with a dopamine agonist.
Maeda T; Sawada K; Itoh Y; Moriwaki K; Mori H
Lab Invest; 1991 Dec; 65(6):679-87. PubMed ID: 1753713
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma.
Eljarmak D; Lis M; Cantin M; Carrière PD; Collu R
Horm Res; 1985; 21(3):160-7. PubMed ID: 3997065
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous sparsely-granulated prolactin-producing pituitary adenomas in aging rats. A prospective study of the effect of bromocriptine.
McComb DJ; Hellmann P; Kovacs K; Scott D; Evans WS; Burdman JA; Thorner MO
Neuroendocrinology; 1985 Sep; 41(3):201-11. PubMed ID: 4047338
[TBL] [Abstract][Full Text] [Related]
11. Cytosuppressive effect of bromocriptine on human prolactinomas: stereological analysis of ultrastructural alterations with special reference to secretory granules.
Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H
Cancer Res; 1986 Mar; 46(3):1507-12. PubMed ID: 3943108
[TBL] [Abstract][Full Text] [Related]
12. [Pathological changes of prolactinomas treated with bromocriptine].
Teramoto A; Takakura K; Fukushima T; Osamura Y
No Shinkei Geka; 1982 Jun; 10(6):619-27. PubMed ID: 7121729
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy.
Itoh J; Kawai K; Serizawa A; Yamamoto Y; Ogawa K; Matsuno A; Watanabe K; Osamura RY
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):364-70. PubMed ID: 11759065
[TBL] [Abstract][Full Text] [Related]
14. Changes in the ultrastructural distribution of prolactin and growth hormone mRNAs in pituitary cells of female rats after estrogen and bromocriptine treatment, studied using in situ hybridization with biotinylated oligonucleotide probes.
Matsuno A; Ohsugi Y; Utsunomiya H; Takekoshi S; Sanno N; Osamura RY; Watanabe K; Teramoto A; Kirino T
Histochem Cell Biol; 1995 Jul; 104(1):37-45. PubMed ID: 7584558
[TBL] [Abstract][Full Text] [Related]
15. Storage and release of secretory granules in human prolactinomas: modification by bromocriptine.
Landolt AM; Osterwalder V; Landolt TA
J Endocrinol; 1987 Jun; 113(3):495-9. PubMed ID: 3625099
[TBL] [Abstract][Full Text] [Related]
16. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.
Eguchi K; Kawamoto K; Uozumi T; Ito A; Arita K; Kurisu K
Endocr J; 1995 Apr; 42(2):153-61. PubMed ID: 7627259
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells.
Landolt AM; Osterwalder V; Landolt TA
Experientia; 1985 May; 41(5):640-2. PubMed ID: 3996537
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-induced prolactinoma in a man.
Gooren LJ; Assies J; Asscheman H; de Slegte R; van Kessel H
J Clin Endocrinol Metab; 1988 Feb; 66(2):444-6. PubMed ID: 3339116
[TBL] [Abstract][Full Text] [Related]
19. Immunofluorescence demonstration of tubulin and actin in estrogen-induced rat prolactinoma cells in vitro. Alteration of their distribution after bromocriptine, colchicine and cytochalasin B treatments.
Niwa J; Mori M; Minase T; Hashi K
Exp Cell Res; 1985 Dec; 161(2):517-24. PubMed ID: 3905419
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
